Significant Ownership of SABBY MANAGEMENT, LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for SABBY MANAGEMENT, LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Robert Grundstein - COO
- Manager location
- Miami Beach, FL
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow SABBY MANAGEMENT, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from SABBY MANAGEMENT, LLC
Significant Ownership of SABBY MANAGEMENT, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| FOXO | FOXO TECHNOLOGIES INC. | Common Stock | 9.9% | $2,493,165 | 249,316,528 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| TPST | Tempest Therapeutics, Inc. | Common Stock | 9.9% | $1,397,913 | 492,223 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| LYRA | Lyra Therapeutics, Inc. | Common Stock | 9.9% | $628,817 | 175,158 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| GVH | Globavend Holdings Ltd | Ordinary Shares | 9.9% | $619,590 | 211,464 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| BDRX | Biodexa Pharmaceuticals Plc | ADSs | 9.9% | $493,974 | 217,600 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| JZXN | Jiuzi Holdings, Inc. | Ordinary Shares | 9.9% | $367,166 | 206,273 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| OGEN | ORAGENICS INC | Common Stock | 9.9% | $354,882 | 412,654 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| INM | InMed Pharmaceuticals Inc. | Common Stock | 9.9% | $333,364 | 280,138 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| APDN | APPLIED DNA SCIENCES INC | Common Stock | 9.9% | $313,452 | 5,224,206 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| UPC | Universe Pharmaceuticals INC | Ordinary Shares | 9.9% | $254,516 | 727,190 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| CYN | Cyngn Inc. | Common Stock | 9.9% | $150,379 | 2,148,268 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| VLCN | Volcon, Inc. | Common Stock | 9.9% | $45,948 | 56,034 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| RNAZ | Transcode Therapeutics, Inc. | Common Stock | 9.9% | $26,431 | 69,555 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| REVB | REVELATION BIOSCIENCES, INC. | Common Stock | 9.6% | $502,733 | 605,702 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| DSY | Big Tree Cloud Holdings Ltd | Ordinary Shares | 6.6% | $1,615,597 | 5,769,988 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| NUWE | Nuwellis, Inc. | Common Stock | 5.4% | $182,957 | 89,685 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| TC | TuanChe Ltd | ADSs | 5% | $115,936 | 146,754 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| BNBX | BNB PLUS CORP. | Common Stock | 4.9% | $690,553 | 217,840 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| RNAZ | Transcode Therapeutics, Inc. | Common Stock | 4.9% | $433,482 | 41,601 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| DUO | Fangdd Network Group Ltd. | ADSs | 4.9% | $243,293 | 1,280,488 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| GCTK | Glucotrack, Inc. | Common Stock | 4.9% | $241,352 | 647,055 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| REVB | REVELATION BIOSCIENCES, INC. | Common Stock | 4.9% | $120,927 | 416,989 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| UPC | Universe Pharmaceuticals INC | Ordinary Shares | 4.9% | $117,504 | 28,111 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| BVXV | Scinai Immunotherapeutics Ltd. | ADSs | 4.9% | $26,727 | 29,051 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| LIPO | LIPELLA PHARMACEUTICALS INC. | Common Stock | 4.9% | $18,701 | 60,325 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| RKDA | Arcadia Biosciences, Inc. | Common Stock | 4.9% | $17,028 | 68,111 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| INM | InMed Pharmaceuticals Inc. | Common Stock | 4.9% | $12,647 | 36,135 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| BJDX | Bluejay Diagnostics, Inc. | Common Stock | 4.9% | $7,173 | 27,587 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| EMPD | Empery Digital Inc. | Common Stock | 1.3% | $2,310,843 | 479,428 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| CYN | Cyngn Inc. | Common Stock | 1% | $305,282 | 77,680 | SABBY MANAGEMENT, LLC | 31 Dec 2025 | ||
| TNXP | Tonix Pharmaceuticals Holding Corp. | Common Stock | 0.7% | $143,694 | 1,306,313 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| IBIO | iBio, Inc. | Common Stock | 0.2% | $3,272 | 19,250 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| RCON | Recon Technology, Ltd | Ordinary Shares | 0% | $0 | 0 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| MOBQ | Mobiquity Technologies, Inc. | Common Stock | 0% | $0 | 0 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| TGA | TREASURE GLOBAL INC | Common Stock | 0% | $0 | 0 | SABBY MANAGEMENT, LLC | 31 Dec 2024 | ||
| PHUN | Phunware, Inc. | Common Stock | 0% | $0 | 0 | SABBY MANAGEMENT, LLC | 31 Dec 2024 |
Schedules 13D/G Reported by SABBY MANAGEMENT, LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.